IP Library Granted Patent US 9,745,376
Granted Patent B2
US 9,745,376 · App. 14/444,701 · Granted Aug 29, 2017

Anti-α

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,745,376
App. No.
14/444,701
Granted
Aug 29, 2017
Kind
B2
Abstract

Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Qmediated diseases.

Claims (10)

1. A DNA encoding a heavy chain of an anti-αvβ6 antibody or antigen-binding fragment thereof, the humanized heavy chain comprising a heavy chain variable region comprising complementarity determining regions (CDRs) 1, 2, and 3 consisting of the amino acid sequences set forth in SEQ ID NOs.: 3, 6, and 9, respectively.

2. A DNA encoding a light chain of an anti-αvβ6 antibody or antigen-binding fragment thereof, the light chain comprising a light chain variable region comprising complementarity determining regions (CDRs) 1, 2, and 3 consisting of the amino acid sequences set forth in SEQ ID NOs.: 12, 14, and 18, respectively.

3. A host cell producing an anti-αvβ6 antibody or antigen-binding fragment thereof, comprising:

a first DNA encoding a heavy chain of the anti-αvβ6 antibody or antigen-binding fragment thereof, the heavy chain comprising a heavy chain variable region comprising complementarity determining regions (CDRs) 1, 2, and 3 consisting of the amino acid sequences set forth in SEQ ID NOs.: 3, 6, and 9, respectively; and

a second DNA encoding a light chain of the anti-αvβ6 antibody or antigen-binding fragment thereof, the light chain comprising a light chain variable region comprising CDRs 1, 2, and 3 consisting of the amino acid sequences set forth in SEQ ID NOs.: 12, 14, and 18, respectively.

4. The host cell of claim 3 , wherein the host cell is a CHO cell.

5. The host cell of claim 3 , wherein the host cell is an NSO cell.

6. A method of producing a soluble anti-αvβ6 antibody or antigen-binding fragment thereof, the method comprising culturing the host cell of claim 3 under conditions that produce the soluble anti-αvβ6 antibody or antigen-binding fragment thereof.

7. The method of claim 6 , wherein the host cell is a CHO cell.

8. The method of claim 6 , wherein the host cell is an NSO cell.

Assignments (3)
CHANGE OF NAME Recorded May 4, 2015
From: BIOGEN IDEC MA INC.
To: BIOGEN MA INC.
Reel/Frame 035571/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2015
From: VIOLETTE, SHELIA M.; WEINREB, PAUL H.; SIMON, KENNETH J.; LEONE, DIANE R.
To: BIOGEN IDEC MA INC.
Reel/Frame 034827/0790 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2015
From: SHEPPARD, DEAN
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 034827/0816 →